NCT04972955View on ClinicalTrials.gov

Predicting Dysglycemia in Individuals With Gestational Diabetes Immediately Postpartum Using Continuous Glucose Monitoring

Active, not recruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

July 4, 2023

Primary Completion Date

July 25, 2025

Study Completion Date

December 1, 2030

Conditions
Gestational DiabetesPrediabetes; Complicating PregnancyType 2 DiabetesPregnancy RelatedGlucose Metabolism DisordersMetabolic DiseaseEndocrine System Diseases
Interventions
DEVICE

Freestyle Libre 2

Participants will wear a continuous glucose monitoring device, the Freestyle Libre 2, for two weeks following delivery.

DEVICE

Freestyle Libre 2

Participants will wear a second continuous glucose monitoring device, the Freestyle Libre 2, for two weeks at 4-6 months postpartum and before their standard of care postpartum bloodwork after having gestational diabetes.

Trial Locations (4)

T2N1N4

University of Calgary, Calgary

R3E3P4

University of Manitoba, Winnipeg

M5T3L9

Mount Sinai Hospital, Toronto

G1V4G2

Universite Laval, Québec

All Listed Sponsors
lead

University of Manitoba

OTHER